- CVAC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
-
Insider
- Institutional
- Shorts
-
SC 13D Filing
CureVac (CVAC) SC 13DCureVac / KfW ownership change
Filed: 24 Aug 20, 5:03pm
A | DH undertook in Section 8 (“Investment commitment DH”) of the Shareholders’ Agreement in relation to the Parties’ share portfolios in CureVac N.V. (NL-Amsterdam) dated 16 June 2020 (“Shareholders’ Agreement”) entered into by the Parties (with the exception of DH-LT Investments GmbH) to invest an amount of EUR 100 million in CureVac N.V. on the occasion of the IPO in order to acquire shares at economic terms and conditions and in particular at a share price corresponding to the issue price of a share in the course of the IPO (“concurrent private placement”) (“Investment Amount”). |
B | DH does not intend to fulfil this obligation personally, but through DH-LT Investments GmbH, with its registered seat in St. Leon Rot and registered in the Commercial Register of the Regional Court (Amtsgericht) of Mannheim under HRB 732866 (“DH-LT”), the sole shareholder of which is DH. |
C | For this reason, the other Parties and DH-LT agree to include DH-LT in the Shareholders’ Agreement on the side of DH by means of this Supplement to the Shareholders’ Agreement. |
1 | Accession of DH-LT to the Shareholders’ Agreement; consent of the other Parties |
1.2 | DH-LT is inter alia obligated pursuant to Section 8, 2nd sentence in conjunction with Section 4.5 of the Shareholders’ Agreement to exercise the rights from the IPO Shares in the context of resolutions of the general meeting on Restricted Items of Resolutions in the same way as the voting rights from the Restricted Shares. |
1.3 | For the avoidance of doubt, it shall be clarified that even upon the accession of DH-LT to the Shareholders’ Agreement as described above, the investment of the Investment Amount is owed only once. |
1.4 | The other Parties hereby consent to DH-LT’s accession to the Shareholders’ Agreement described in Section 1.1. |
2 | Notices to be sent to DH-LT |
3 | Final provisions |
3.1 | The other provisions of the Shareholders’ Agreement remain unchanged and continue to apply. |
3.2 | Terms which are defined in this Supplement (including its title reference and preamble) shall have the same meaning if they appear in small caps in the typeface. If terms appear in small caps in the typeface of this Supplement which are not separately defined in this Supplement, they shall have the meaning attributed to them in the Shareholders’ Agreement. |
3.3 | This Supplement is subject to the laws Federal Republic of Germany. |
3.4 | Revisions or amendments to this Supplement or an agreement on its cancellation must be made in writing to be effective. The written form shall not be fulfilled in this respect by means of transmission by means of telecommunication transmission (fax), exchange of letters, electronic form (e-mail) or other text form (Section 126b German Civil Code (Bürgerliches Gesetzbuch – BGB)). The requirement of written form agreed herein may only be waived or amended if the requirement of written form is complied with. Oral agreements do not exist. |
Walldorf, | [handwritten: 14 August 2020] | ||
[signature] | |||
Dietmar Hopp | |||
Frankfurt, | |||
KfW | |||
Dr Nils Reichhelm | Dr Elina Pradkhan | ||
Walldorf, | [handwritten: 14 August 2020] | ||
dievini Hopp BioTech holding GmbH& Co. KG represented by | |||
dievini Verwaltungs GmbH, the latter in turn represented by: | |||
[signature] | [signature] | ||
Dietmar Hopp | Dr Mathias Hothum |
St. Leon-Rot, | [handwritten: 14 August 2020] | ||
DH-LT Investments GmbH | |||
[signature] | |||
Dietmar Hopp |
Walldorf, | |||
Dietmar Hopp | |||
Frankfurt, | [handwritten: 12 August 2020] | ||
KfW | |||
[signature] | [signature] | ||
Dr Nils Reichhelm | Dr Elina Pradkhan | ||
Walldorf, | |||
dievini Hopp BioTech holding GmbH& Co. KG represented by | |||
dievini Verwaltungs GmbH, the latter in turn represented by: | |||
Dietmar Hopp | Prof Dr Christof Hettich |